Companies › Wanbangde Pharmaceutical Group
2 active drug programs in 3 registered trials: 2 Phase 4, 1 Phase 2; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ginkgo leaf dropping pill Ginkgo biloba extract (neuroprotection and cognitive enhancement) | – | Phase 4 | Cognitive Impairment After Brain Injury | Dec 2026 |
| Huperzine A Controlled-Release Tablets Acetylcholinesterase inhibitor | ACHE | Phase 4 | Cognitive Impairment After Brain Injury; Alzheimer Dementia | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06704334 | Ginkgo leaf dropping pill | Phase 4 | Cognitive Impairment After Brain Injury | Neurology | Dec 2026 |
| NCT06704334 | Huperzine A Controlled-Release Tablets | Phase 4 | Cognitive Impairment After Brain Injury | Neurology | Dec 2026 |
| NCT07066826 | Huperzine A Controlled-Release Tablets | Phase 2 | Alzheimer Dementia | Neurology | Aug 2028 |
Alpha Cognition Pharmasoft Suven Life Sciences Bigespas JYAMS PET Research & Development
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.